Aron Markovics is a disciplined and analytically minded student with deep interests in finance, global markets, and quantitative decision-making. Known for his precision, intellectual curiosity, and strong work ethic, Aron consistently brings sharp insights and thoughtful perspectives to team discussions. He thrives in structured, high-expectation environments and approaches every challenge with focus and professionalism. Outside the classroom, he enjoys exploring market trends, refining his technical skills, and pursuing long-term personal and academic growth.

MediWound develops enzymatic therapies for burns and chronic wounds, anchored by NexoBrid — an FDA-approved, surgery-sparing debridement treatment gaining traction in U.S. burn centers. The company sits at the intersection of rising demand for advanced wound care and hospital pressure to reduce OR time and staffing needs. With a lean cost structure and a clear path to scaling revenue, MediWound trades at a steep discount to wound-care peers despite differentiated tech and growing regulatory support. The upside case is straightforward: commercial ramp + pipeline validation driving a rerating as MDWD becomes a focused bet on next-gen debridement.